SCHEMBL1684643

SCHEMBL1684643

Cc1ccc(Nc2nccc(-c3c(C)nc4ccccn34)n2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 12/20 0.86
CDK4 P11802 6/20 0.86
CCNE1 P24864 5/20 0.86
CDK1 P06493 1/20 0.64
KDM4E B2RXH2 4/20 0.60
ALDH1A1 P00352 4/20 0.60
GAA P10253 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
LMNA P02545 2/20 0.60
MAPT P10636 2/20 0.60
HTT P42858 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
HPGD P15428 2/20 0.60
MEN1 O00255 1/20 0.60
ALOX12 P18054 1/20 0.60
KMT2A Q03164 1/20 0.60
KDR P35968 1/20 0.55
PTK2 Q05397 1/20 0.55
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1684709 0.91 CDK2 (0.83) CDK2CDK4CCNE1CDK1KDM4E
SCHEMBL1684889 0.91 CDK2 (1.00) CDK2CDK4CCNE1CDK1KDM4E
SCHEMBL1684885 0.91 CDK2 (0.83) CDK2CDK4CCNE1CDK1KDM4E
SCHEMBL1684908 0.89 CDK2 (0.79) CDK2CDK4CCNE1CDK1MEN1
SCHEMBL1684684 0.89 CDK2 (0.79) CDK2CDK4CCNE1CDK1KDM4E
SCHEMBL1684845 0.87 CDK2 (0.76) CDK2CDK4CCNE1CDK1KDM4E
SCHEMBL1684670 0.87 CDK2 (0.76) CDK2CDK4CCNE1CDK1KDM4E
SCHEMBL1684693 0.87 CDK2 (0.80) CDK2CDK4CCNE1CDK1GSK3B
SCHEMBL1684673 0.86 CDK2 (0.74) CDK2CDK4CCNE1CDK1KDM4E
SCHEMBL1684810 0.86 CDK2 (0.74) CDK2CDK4CCNE1CDK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A CDK2 1442/4885CDK4 1500/4885CCNE1 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.